A method of selectively killing gram negative bacteria and inhibiting the growth of gram positive bacteria in a pharmaceutical preparation comprising an active agent selected from the group consisting of treprostinil and treprostinil sodium, the method comprising supplying the active agent with a buffer comprising glycine and having a pH of greater than 10 with low buffer capacity. view more

The method of claim 1, wherein the active agent is treprostinil sodium.

The method of claim 1, wherein the buffer further comprises sodium hydroxide.

The method of claim 1, wherein the buffer has a pH between about 10 to about 12 with low buffer capacity.

The method of claim 4, wherein the buffer has a pH between about 10.2 to about 10.8 with low buffer capacity.

The method of claim 1, wherein the active agent is supplied at a concentration between about 0.001 mg/mL to about 1 mg/mL.

The method of claim 2, wherein the treprostinil sodium is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.

The method of claim 1 further comprising injecting the pharmaceutical preparation into a mammal in need thereof.

The method of claim 4, wherein the pharmaceutical preparation is injected intravenously into a mammal in need thereof.

A method of reducing the occurrence of blood stream infections in a mammal being treated with an active agent comprising administering to the mammal the active agent with a buffer comprising glycine and having a pH of greater than 10, wherein the active agent is selected from the group consisting of treprostinil and treprostinil sodium, and wherein the administration reduces the gram negative bacteria and inhibits the growth of gram positive bacteria. view more

The method of claim 11, wherein the human subject has pulmonary arterial hypertension.

The method of claim 11, where in the active agent is administered intravenously.

The method of claim 11, wherein the active agent is treprostinil sodium.

The method of claim 11, wherein the buffer further comprises sodium hydroxide and has a pH between about 10.2 to about 10.8.

The method of claim 11, wherein the buffer has a pH between about 10 to about 12 with low buffer capacity.

The method of claim 16, wherein the buffer has a pH between about 10.2 to about 10.8 with low buffer capacity.

The method of claim 11, wherein the active agent is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/ml.

The method of claim 14, wherein the treprostinil sodium is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.

The method of claim 1 wherein the administering is injecting the pharmaceutical preparation into a mammal in need thereof.

The composition of claim 22, wherein the solution further comprises sodium hydroxide.

A stereoselectively produced isomeric compound according to the following formula: <CWU><CHEM-US ID="CHEM-US-00026"><CHEMCDX ID="CHEMCDX-00026" ALT="chemistry chemdraw file" FILE="US06765117-20040720-C00026.CDX"/><CHEMMOL ID="CHEMMOL-00026" D="EMI-C00026" ALT="embedded image" HE="68.18175" WI="126.24255" FILE="US06765117-20040720-C00026.TIF"/> that is produced by a process for making 9-deoxy-PGF1-type compounds, the process comprising cyclizing a starting compound of the formula: into a compound of the following formula: by intramolecular cyclization of the enyne, wherein Z is O, S, CH2, or NR8 in which R8 is H, alkyl or aryl; X is H, CN, OR9, or COOR9 in which R9 is H, alkyl, a pharmacologically acceptable cation, THP or TBDMS; wherein n is 0, 1, 2, or 3; wherein Y1 is trans-CH═CH—, cis-CH═CH—, CH2(CH2)m-, or —C≡C—; m is 1,2, or 3; wherein R1 is an alcohol protecting group; wherein R7 is (1) —C2H2p—CH3, wherein p is an integer from one to 5, inclusive, (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R7 is phenoxy or substituted phenoxy, only when R3 and R4 are hydrogen or methyl, being the same or different, (3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, (4) cis-CH═CH—CH2—CH3, (5) —(CH2)2—CH(OH)—CH3, or (6) —(CH2)3—CH═C(CH3)2; wherein —C(L1)—R7 taken together is (1) (C4-C7)cycloalkyl optionally substituted by one to 3 (C1-C5) alkyl; (2) 2-(2-furyl)ethyl, (3) 2-(3-thienyl)ethoxy, or (4) 3-thienyloxymethyl; wherein M1 is α-OH:β-R5 or α-R5:β-OH or α-OR1:β-R5 or α-R5:β-OR1, wherein R5 is hydrogen or methyl and R1 is an alcohol protecting group; and wherein L1 is α-R3:β-R4, α-R4:β-R3, or a mixture of α-R3:β-R4 and α-R4:β-R3, wherein R3 and R4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R3 and R4 is fluoro only when the other is hydrogen or fluoro. view more

The stereoselectively produced isomeric compound of claim 1, wherein Z is O, n is 1, X is COOH, Y<HIL><SB>1 </SB></HIL>is -CH<HIL><SB>2</SB></HIL>CH<HIL><SB>2</SB></HIL>- M<HIL><SB>1 </SB></HIL>is α-OH:β-R<HIL><SB>5</SB></HIL>, wherein R<HIL><SB>5 >and R4 are hydrogen and R7 is butyl. view more

A steroselectively produced isomeric compound according to the following formula: <CWU><CHEM-US ID="CHEM-US-00029"><CHEMCDX ID="CHEMCDX-00029" ALT="chemistry chemdraw file" FILE="US06765117-20040720-C00029.CDX"/><CHEMMOL ID="CHEMMOL-00029" D="EMI-C00029" ALT="embedded image" HE="73.9368" WI="176.42205" FILE="US06765117-20040720-C00029.TIF"/> that is produced by a process for making 9-deoxy-PFG1-type compounds, the process comprising cyclizing a starting compound of the formula: into a compound of the following formula: by intramolecular cyclization of the enyne, wherein Z is O, S, CH2, or NR8 in which R8 is H, alkyl or aryl; X is H, CN, OR9, or COOR9 in which R9 is H; wherein n is 0, 1, 2, or 3; wherein Y1 is trans-CH=CH-, cis-CH=CH-, -CH2(CH2)m-, or -C=C-; m is 1,2, or 3; wherein R1 is an alcohol protecting group; wherein R7 is (5) -CpH2p-CH3, wherein p is an integer from one to 5, inclusive, (6) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R7 is phenoxy or substituted phenoxy, only when R3 and R4 are lydrogen or methyl, being the same or different, (7) phenyl, bnezyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoyx, with the proviso that not more than two substituents are other than alkyl, (8) cis-CH=CH-CH2-CH3, (9) -(CH2)2-CH(OH)-CH3, or (10) -(CH2)3-CH=C(CH3)2; wherein -C(L1)-R7 taken together is (11) (C6-C7)cycloalkyl optionally substituted by one to 3 (C1-C5) alkyl; (12) 2-(2-furyl)ethyl, (13) 2-(3-thienyl)ethoxy, or (14) 3-thienyloxymethyl; wherein M1 is α-OH:β-R5 or α-R5:β-OH or α-OR1:β-R5 or α-R5:β-OR1, wherein R5 is hydrogen or methyl and R1 is an alcohol protecting group; and wherein L1 is α-R3:β-R4, α-R4:β-R3, or a mixture of α-R3:β-R4 and α-R4:β-R3, wherein R3 and R4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R3 and R4 is fluoro only when the other is hydrogen or fluoro. view more

A steroselectively produced isomeric compound in pharmacologically acceptable salt form according to the following formula: <CWU><CHEM-US ID="CHEM-US-00032"><CHEMCDX ID="CHEMCDX-00032" ALT="chemistry chemdraw file" MOL ID="CHEMMOL-00032" ALT="chemistry mol file" FILE="US06765117-20040720-C00032.MOL"/> that is produced by process for making 9-deoxy-PGF1-type compounds, the process comprising cyclizing a starting compound of the formula: into a compound of the following formula: by intramolecular cyclization of the enyne, wherein Z is O, S, CH2, or NR8 in which R8 is H, alkyl or aryl; X is H, CN, OR9, or COOR9 in which R9 is a pharmacologically acceptable cation; wherein n is 0, 1, 2, or 3; wherein Y1 is trans-CH=CH-, cis-CH=CH-, -CH2(CH2)m-, or -C=C-; m is 1,2, or 3; wherein R1 is an alcohol protecting group; wherein R7 is (1) -CpH2p-CH3, wherein p is an integer from one to 5, inclusive, (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R7 is phenoxy or substituted phenoxy, only when R3 and R4 are hydrogen or methyl, being the same or different, (3) phenyl ,benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, tow or three chloro, fluoro, tribluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoyx, with the proviso that not more than two substituents are other than alkyl, (4) cis-CH=CH-CH2-CH3, (5) -(CH2)2-CH(OH)-CH3, or (6) -(CH2)3-CH=C(CH3)2; wherein -C(L1)-R7 taken together is (1) (C4-C7)cycloalkyl optionally substituted by one to 3 (C1-C5) alkyl; (2) 2-(2-furyl)ethyl, (3) 2-(3-thienyl)ethoxy, or (4) 3-thienyloxymethyl; wherein M1 is α-OH:β-R4 or α-R5:β-OH or α-OR1:β-R5 or α-R5:β-OR1, wherein R5 is hydrogen or methyl and R1 is an alcohol protecting group; and wherein L1 is α-R3:β-R4, α-R4:β-R3, or a mixture of α-R3:β-R4 and α-R4:β-R3, wherein R3 and R4 are kydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R3 and R4 is fluoro only when the other is hydrogen or fluoro. view more